Trk kinase inhibitors as new treatments for cancer and pain.
Expert Opin Ther Pat
; 19(3): 305-19, 2009 Mar.
Article
em En
| MEDLINE
| ID: mdl-19441906
ABSTRACT
BACKGROUND:
Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins. Trks play important roles in pain sensation as well as tumour cell growth and survival signaling. Thus, inhibitors of Trk receptor kinases might provide targeted treatments for pain and cancer.OBJECTIVE:
This paper reviews those patent applications since 2002 claiming small-molecule inhibitors of Trk receptor kinases.METHODS:
Primary literature and patents were searched with SciFinder and Google Scholar. Patents were selected based on their relevance to Trks and were evaluated and representative compounds were listed as examples. RESULTS/CONCLUSION:
Several series of Trk inhibitors with excellent in vitro potencies have been reported and a number of compounds have gone into the clinic. It should be noted that few of these inhibitors are Trk selective, demonstrating that targeting Trk kinases for treatment of pain and/or cancer offers a promising but also challenging approach.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Receptor trkA
/
Receptor trkB
/
Receptor trkC
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article